The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia
Open Access
- 8 December 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (24) , 6353-6361
Abstract
Identification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detection/readout complexities, abnormality of κ and λ serum-free light chain ratio [sFLC (κ/λ)] was proposed as a straightforward prognosticator in CLL. By analyzing 449 therapy-naive patients, we show that an abnormal sFLC(κ/λ), along with CD38, ZAP-70, IGHV mutations, cytogenetics and stage, independently predicts treatment-free survival (TFS) but becomes prognostically irrelevant if the cumulative amount of clonal and nonclonal FLCs [sFLC(κ + λ)], a variable associated with cytogenetic risk, exceeds the threshold of 60.6 mg/mL. Patients with sFLC(κ + λ) above cut-off displayed a poorer TFS outcome, irrespective of sFLC(κ/λ). Only ZAP-70, cytogenetics, stage, and TFS remained associated with sFLC(κ + λ) in a multivariate model. By assigning 1 point each for these variables, the 3-year probability of TFS was 94.8%, 84.5%, 61.6%, and 21.1% for patients scoring 0, 1, 2, and 3 + 4, respectively (P < .0001). These data, and the demonstration that monoclonal and polyclonal B cells concur to FLC synthesis in tumor tissues, suggest that sFLC(κ/λ) and sFLC(κ + λ) mirror distinct biologic processes in CLL. sFLC(κ + λ) assessment represents a sensitive and cost-effective tool for identifying CLL patients requiring early treatment.Keywords
This publication has 32 references indexed in Scilit:
- Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemiaEuropean Journal of Haematology, 2010
- Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)Best Practice & Research Clinical Haematology, 2010
- Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2008
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseasesTrends in Pharmacological Sciences, 2008
- Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cellsHaematologica, 2008
- Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light ChainsClinical Chemistry, 2002
- Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and UrineClinical Chemistry, 2001